EDMONTON, ALBERTA--(Oct. 26, 2017)
- Successful execution of JuventeDC Inc. acquisition marks an important step in Ceapro's strategic market diversification business plan.
- New anti-aging skin care product line represents $5B market opportunity and utilizes Ceapro's active ingredients beta glucan and avenanthramides.
Ceapro Inc., a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced recently its entry into the end-user cosmeceuticals market through the acquisition of Quebec-based company, JuventeDC Inc. Mr. Jean-Guy Boulet, Founder of Juvente, will join Ceapro as General Manager of this newly-formed, fully-owned subsidiary of Ceapro.
Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, stated, "We have worked diligently over the last twelve months with different companies to evaluate opportunities to expand our product portfolio with the development of formulations that utilize our two value drivers, beta glucan and avenanthramides. Juvente successfully developed very impressive formulations, and today, we are thrilled with the completion of the acquisition of Juvente.